Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

ALEXION PHARMACEUTICALS

(ALXN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/09/2019 09/10/2019 09/11/2019 09/12/2019 09/13/2019 Date
106.4(c) 109.6(c) 108.9(c) 108.26(c) 107.4(c) Last
2 493 527 3 798 300 1 952 522 2 358 301 1 891 446 Volume
+2.47% +3.01% -0.64% -0.59% -0.79% Change
More quotes
Financials (USD)
Sales 2019 4 839 M
EBIT 2019 2 717 M
Net income 2019 1 907 M
Finance 2019 535 M
Yield 2019 -
Sales 2020 5 513 M
EBIT 2020 3 000 M
Net income 2020 2 044 M
Finance 2020 2 363 M
Yield 2020 -
P/E ratio 2019 12,7x
P/E ratio 2020 11,9x
EV / Sales2019 4,87x
EV / Sales2020 3,94x
Capitalization 24 082 M
More Financials
Company
Alexion Pharmaceuticals specializes in the research and development of therapeutic products used in treating hematological and cardiovascular diseases, auto-immune diseases, and cancers. At the end of 2017, the group had a portfolio of 5 products in clinical development. Net sales are distributed... 
Sector
Pharmaceuticals
Calendar
10/26Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS
09/10Bridgebio Grants Japanese Rights to Eidos' ag10 to Alexion
AQ
09/09ALEXION : and BridgeBio Announce Japanese License Agreement for Eidos' Transthyr..
BU
09/05ALEXION PHARMACEUTICALS : Pharma Shares Fall After EU Patent Decision
DJ
09/04ALEXION PHARMACEUTICALS : to Present at the 17th Annual Morgan Stanley Global He..
BU
09/03Stocks to Watch: Alphabet, H&R Block, Conn's, and More
DJ
09/03Stocks to Watch: Alphabet, H&R Block, and Alexion Pharmaceuticals
DJ
09/01ALEXION PHARMACEUTICALS : Mike Page, Alexion Pharmaceuticals Invites You to SMi'..
AQ
08/30Alexion Down Over 11%, On Pace for Largest Percent Decrease Since December 20..
DJ
08/28ALEXION PHARMACEUTICALS : European Commission Approves SOLIRIS for the Treatment..
AQ
08/28ALEXION PHARMACEUTICALS : Announces Upcoming Data Presentations at 35th Congress..
BU
More news
Analyst Recommendations on ALEXION PHARMACEUTICALS
More recommendations
Stock Trading Strategies
ALEXION PHARMACEUTICALS - 09/04
Back on an important level
BUY
More Stock Trading Analysis
Sector news : Biopharmaceuticals
03:27aH LUNDBECK : Lundbeck buys Alder in $2 billion migraine treatment move
RE
02:48aA Plan to Fight Hep C -- WSJ
DJ
01:50aSANOFI : Abbott to Collaborate on Glucose Sensing, Insulin Delivery Data
DJ
09/14NOVARTIS : Trial and Error -2-
DJ
09/14NOVARTIS : Trial and Error
DJ
More sector news : Biopharmaceuticals
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 155,48  $
Last Close Price 107,40  $
Spread / Highest target 71,3%
Spread / Average Target 44,8%
Spread / Lowest Target 12,7%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
John J. Orloff Executive VP, Head-Research & Development
Andreas Rummelt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS10.31%24 082
CSL LIMITED25.08%72 022
BIOGEN INC.-21.36%43 646
GRIFOLS18.34%18 046
SAMSUNG BIOLOGICS CO LTD--.--%16 471
BIOMARIN PHARMACEUTICAL INC.-14.68%13 038